Janice Chen, co-founder and CTO of Mammoth Biosciences, shares how CRISPR gene editing is transforming the future of medicine. A trailblazer trained in Nobel laureate Jennifer Doudna’s lab at UC Berkeley, Janice is developing powerful new tools that go beyond traditional CRISPR, ushering in a new era of in vivo gene editing that can correct the root cause of disease. Janice Chen is the co-founder and CTO of Mammoth Biosciences, a biotechnology company based in the San Francisco Bay Area that is harnessing the diversity of nature to develop in vivo gene editing therapies. Through its discovery of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Janice received her PhD from the lab of Nobel Laureate Jennifer Doudna at University of California, Berkeley, where she investigated mechanisms of CRISPR-Cas proteins and is an inventor of several CRISPR-based technologies. Janice's work has been recognized by several organizations, including Forbes 30 Under 30 in Healthcare, Endpoints Top 20 Women in Biopharma, and MIT Technology Review 35 Innovators Under 35. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at https://www.ted.com/tedx